erythropoietic protoporphyria

And just now, today, we announced that we closed the acquisition of Spivigo.

And another potential product that is right now being reviewed by FDA for the treatment of EPP and XLP.

So if you look at this, you know, the commitments that Leo has to those patients and the growth that we're seeing, especially here in the US with those products that we're bringing, it's something extraordinary.

And, you know, I'm just really happy to be part of this team and have an opportunity to lead this great team as we go on this journey.

So to start off, could you provide an overview of EPP and XLP? What are the common symptoms, current treatment options, and what that disease burden looks like for patients?

Yeah, thanks for this question.

And here at Leo, we always start with patients and their caregivers.

As you will learn, EPP and XLP, the first symptoms often start in childhood.

Melanotan I is actually FDA-approved for a very, very specific, very rare skin condition that causes extreme sensitivity to light.

Erythropoietic protoporphyria.

Or EPP for short.

It's actually so rare that Dr. Grewal has never seen the condition in her medical career.

Its incidence has been estimated at two to five cases per million people.

You would know if you had this because you have symptoms when you're a young child.

Children have very severe, painful, uh, photosensitivity after exposure to sunlight or even visible light, which can come from even indoor lights, laptop screens.

EPP causes extreme swelling, burning, and pain when exposed to certain light.